Globus Medical (NYSE:GMED) Updates FY 2026 Earnings Guidance

Globus Medical (NYSE:GMED) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of 4.700-4.800 for the period, compared to the consensus earnings per share estimate of 4.470. The company issued revenue guidance of $3.2 billion-$3.2 billion, compared to the consensus revenue estimate of $3.2 billion.

Globus Medical Trading Down 4.7%

Shares of NYSE GMED opened at $85.05 on Friday. Globus Medical has a 12 month low of $51.79 and a 12 month high of $101.40. The firm has a market capitalization of $11.50 billion, a PE ratio of 21.59, a price-to-earnings-growth ratio of 2.09 and a beta of 1.00. The firm has a fifty day simple moving average of $89.86 and a two-hundred day simple moving average of $86.65.

Globus Medical (NYSE:GMED) last issued its quarterly earnings data on Thursday, May 7th. The medical device company reported $1.12 EPS for the quarter, topping the consensus estimate of $0.92 by $0.20. Globus Medical had a net margin of 18.30% and a return on equity of 12.57%. The business had revenue of $759.85 million during the quarter, compared to analyst estimates of $740.35 million. During the same period in the prior year, the business earned $0.68 EPS. The company’s revenue for the quarter was up 27.0% on a year-over-year basis. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. On average, sell-side analysts predict that Globus Medical will post 4.46 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have commented on GMED shares. Piper Sandler restated an “overweight” rating and issued a $115.00 price objective (up from $90.00) on shares of Globus Medical in a report on Thursday, January 8th. Canaccord Genuity Group upped their target price on shares of Globus Medical from $105.00 to $112.00 and gave the stock a “buy” rating in a research report on Friday, January 9th. Wells Fargo & Company raised shares of Globus Medical to a “strong-buy” rating in a research report on Wednesday, March 18th. Barclays upped their target price on shares of Globus Medical from $118.00 to $123.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. Finally, TD Cowen raised shares of Globus Medical to a “strong-buy” rating in a research report on Tuesday, January 27th. Three research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $104.64.

Insider Buying and Selling at Globus Medical

In other news, EVP Kelly Huller sold 20,000 shares of the company’s stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $94.50, for a total value of $1,890,000.00. The transaction was disclosed in a filing with the SEC, which is available through this link. 18.38% of the stock is owned by corporate insiders.

Institutional Trading of Globus Medical

Hedge funds and other institutional investors have recently modified their holdings of the business. Wealthspire Advisors LLC grew its position in Globus Medical by 11.4% during the 4th quarter. Wealthspire Advisors LLC now owns 2,645 shares of the medical device company’s stock valued at $231,000 after purchasing an additional 271 shares during the last quarter. Integrated Wealth Concepts LLC purchased a new stake in Globus Medical during the 4th quarter valued at about $217,000. Johnson Investment Counsel Inc. purchased a new stake in Globus Medical during the 4th quarter valued at about $214,000. Cresset Asset Management LLC purchased a new stake in Globus Medical during the 2nd quarter valued at about $211,000. Finally, Dark Forest Capital Management LP purchased a new stake in Globus Medical during the 3rd quarter valued at about $210,000. 95.16% of the stock is owned by hedge funds and other institutional investors.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.